Novo Nordisk gets obesity drug approved in Canada

The pharmaceutical company has received marketing authorization for Wegovy from Health Canada, it reports in a press release.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

by christopher due karlsson, translated by catherine brett

Published: 26.11.21 at 07:31

The Canadian health agency, Health Canada, has approved Novo Nordisk's obesity drug Wegovy.

This was revealed in a press release on Thursday, which also stated that the company expects to launch the drug in the country in fall 2022.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Photo: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.